Included in this focus is the small molecule inhibitor - SI-2 - developed in our laboratory to target steroid receptor coactivator (SRC) members such as SRC-3 (SRC-3/NCOA3/AIB1/RAC3) and SRC-1/2 (SRC-1/NCOA1 and SRC-2/NCOA2/TIF2)6 All members of this oncogenic family of coactivators are overexpressed in a broad array of cancer subtypes7. Here, NCOA1 is linked to cancer.